Drugs giant GlaxoSmithKline has reported positive results from an initial study into its development of a drug for HIV treatment.
ViiV Healthcare, a global HIV firm established by Glaxo and Pfizer, and Shionogi & Co announced this morning that the SPRING-2 (ING113086) - the Phase III study of the investigational integrase inhibitor dolutegravir in treatment-nave adults with HIV-1 - met its primary objective, showing non-inferiority of dolutegravir to raltegravir.
"The SPRING-2 findings indicate that once daily unboosted dolutegravir may offer people living with HIV an additional treatment option in the future," sid ViiV's Chief Medica Officer John Pottage.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"These are the first large-scale safety and efficacy data in nave patients, and we look forward to seeing further data in 2012 to build a more comprehensive picture of the role of dolutegravir," he said.
During a period of 48 weeks, 88% of study participants on the one-daily drug were "virologcially supressed" compared with 85% of participants on raltegravir (twice daily).
Shionogi & Co's Chief Executive Officer, Tsutae Nagata, said that the findings mark an "important milestone" for dolutegravir and the Shionogi-ViiV joint venture.
BC
-
Who is the richest person in the world?The top five richest people in the world have a combined net worth of $825 billion. Who takes the crown for the richest person in the world?
-
Top 10 stocks with highest growth over past decade - from Nvidia, Microsoft to Netflix, which companies made you the most money?
We reveal the 10 global companies with the biggest returns since 2013. One firm has posted an astonishing 9,870% return, meaning a £1,000 investment would now be worth almost £82,000.
